SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization.
SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization.
复制标题
DOI:
10.1016/j.celrep.2021.109017
复制
发表时间:
2021-04-20
期刊:
影响因子:
8.8
通讯作者:
Pöhlmann S
中科院分区:
文献类型:
--
作者:
Hoffmann M;Zhang L;Krüger N;Graichen L;Kleine-Weber H;Hofmann-Winkler H;Kempf A;Nessler S;Riggert J;Winkler MS;Schulz S;Jäck HM;Pöhlmann S
Transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from humans to farmed mink has been observed in Europe and the US. In the infected animals, viral variants arose that harbored mutations in the spike (S) protein, the target of neutralizing antibodies, and these variants were transmitted back to humans. This raised concerns that mink might become a constant source of human infection with SARS-CoV-2 variants associated with an increased threat to human health and resulted in mass culling of mink. Here, we report that mutations frequently found in the S proteins of SARS-CoV-2 from mink are mostly compatible with efficient entry into human cells and its inhibition by soluble angiotensin-converting enzyme 2 (ACE2). In contrast, mutation Y453F reduces neutralization by an antibody with emergency use authorization for coronavirus disease 2019 (COVID-19) therapy and sera/plasma from COVID-19 patients. These results suggest that antibody responses induced upon infection or certain antibodies used for treatment might offer insufficient protection against SARS-CoV-2 variants from mink. Transmission of SARS-CoV-2 between humans and farmed mink has caused concern because viruses from mink have acquired mutations in the spike protein. Hoffmann et al. show that these mink-specific mutations do not increase entry into human cells but do cause partial evasion from neutralization by a therapeutic antibody and convalescent plasma/sera.
登录
查看更多内容
DOI:
10.1056/nejmoa2034577
发表时间:
2020-12-31
期刊:
The New England journal of medicine
影响因子:
--
作者:
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者:
C4591001 Clinical Trial Group
影响因子:
64.8
作者:
Plante JA;Liu Y;Liu J;Xia H;Johnson BA;Lokugamage KG;Zhang X;Muruato AE;Zou J;Fontes-Garfias CR;Mirchandani D;Scharton D;Bilello JP;Ku Z;An Z;Kalveram B;Freiberg AN;Menachery VD;Xie X;Plante KS;Weaver SC;Shi PY
通讯作者:
Shi PY
DOI:
10.1126/science.abe5901
发表时间:
2021-01-08
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Oude Munnink BB;Sikkema RS;Nieuwenhuijse DF;Molenaar RJ;Munger E;Molenkamp R;van der Spek A;Tolsma P;Rietveld A;Brouwer M;Bouwmeester-Vincken N;Harders F;Hakze-van der Honing R;Wegdam-Blans MCA;Bouwstra RJ;GeurtsvanKessel C;van der Eijk AA;Velkers FC;Smit LAM;Stegeman A;van der Poel WHM;Koopmans MPG
通讯作者:
Koopmans MPG
影响因子:
5.4
作者:
Kleine-Weber H;Elzayat MT;Wang L;Graham BS;Müller MA;Drosten C;Pöhlmann S;Hoffmann M
通讯作者:
Hoffmann M
影响因子:
56.9
作者:
Cai, Yongfei;Zhang, Jun;Chen, Bing
通讯作者:
Chen, Bing